- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.11. | Filament Health Announces Third Quarter 2025 Financial Results And Operational Highlights | 3 | CNW | ||
| 11.08. | Filament Health Corp. reports Q2 results | 2 | Seeking Alpha | ||
| 11.08. | Filament Health Announces Second Quarter 2025 Financial Results And Operational Highlights | 1 | CNW | ||
| FILAMENT HEALTH Aktie jetzt für 0€ handeln | |||||
| 31.07. | Filament Health Announces First-ever Compassionate Use Approval For Psilocybin In The European Union | 1 | CNW | ||
| 24.07. | Filament Health Announces Two Phase 2 Research Trials In Partnership With University College London | 1 | CNW | ||
| 08.07. | Jaguar Health, Inc.: Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health | 532 | ACCESS Newswire | Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications SAN FRANCISCO, CA / ACCESS Newswire / July 8, 2025 /
Jaguar Health, Inc.
(NASDAQ:JAGX)
... ► Artikel lesen | |
| 07.07. | Filament Health Announces Fda Authorization Of Phase 2 Clinical Trial Studying Psilocybin For Alcohol Use Disorder And Post-traumatic Stress Disorder In Veterans And First Responders | 1 | CNW | ||
| 17.06. | Filament Health Enters Into Exclusive License Agreement With University Of Alabama At Birmingham For Data From A Clinical Trial Of Psilocybin For The Treatment Of Cocaine Use Disorder | 2 | CNW | ||
| 11.06. | Filament Health Announces Authorization Of Phase 2 Clinical Trial Studying Botanical Psilocybin For Prolonged Grief Disorder | 1 | CNW | ||
| 22.05. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.05.2025 | 796 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 22.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.05.2025.ISIN NameCA31685W1068 FILAMENT... ► Artikel lesen | |
| 22.05. | XFRA 7QS: AUSSETZUNG/SUSPENSION | 258 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILFILAMENT HEALTH... ► Artikel lesen | |
| 19.05. | Filament Health Corp.: Filament Health Announces Voluntary Delisting From Cboe Canada | 201 | PR Newswire | VANCOUVER, BC, May 19, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (CBOE: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic... ► Artikel lesen | |
| 09.05. | Filament Health Corp.: Filament Health Announces First Quarter 2025 Financial Results And Operational Highlights | 118 | PR Newswire | VANCOUVER, BC, May 8, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (CBOE: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic... ► Artikel lesen | |
| 04.04. | Filament Health Corp.: Filament Health Announces Private Placement And Intention To Voluntarily Delist From Cboe Canada | 183 | PR Newswire | Financing driven by existing investor Negev and Filament's Board of Directors
Company also announces intention to voluntarily delist from Cboe Canada
VANCOUVER... ► Artikel lesen | |
| 01.04. | Filament Health Corp.: Filament Health Reports Q4 And Year End 2024 Financial Results And Operational Highlights | 147 | PR Newswire | VANCOUVER, BC, April 1, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic... ► Artikel lesen | |
| 17.03. | Filament Health Corp.: Filament Health Announces Positive Data From Phase 2 Study Of Pex010 In Patients With Alcohol Use Disorder | 128 | PR Newswire | Open-label study at Psychiatric Centre Copenhagen found that alcohol consumption significantly decreased amongst participants dosed with Filament's botanical psilocybin... ► Artikel lesen | |
| 06.02. | Jaguar Health, Inc.: Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference | 510 | ACCESS Newswire | Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as... ► Artikel lesen | |
| 07.01. | Jaguar Health, Inc.: Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum | 506 | ACCESS Newswire | Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 34,580 | +1,26 % | Black Friday: DAX explodiert und BioTech ist wieder en Vogue: Achtung 100 % bei Bayer, Vidac Pharma und Novo Nordisk möglich | Die Börse hat sich aus der Konsolidierung wieder befreien können, weiter geht nun der Aufwärts-Move zum Jahresende. Beim Leverkusener Pharma-Konzern Bayer gibt es erst Lichtblicke und Vidac Pharma wechselt... ► Artikel lesen | |
| AURORA CANNABIS | 3,810 | -1,30 % | Droht 2026 gewaltiges Beben?: Das große Zittern beginnt für Canopy Growth, Tilray, Aurora Cannabis & Co. | © Foto: adobe.stock.comDas Jahr 2025 war in vielerlei Hinsicht ein schwieriges Jahr für den Cannabis-Sektor. Eine grundlegende Verbesserung der fundamentalen Rahmenbedingungen blieb aus. Was könnte... ► Artikel lesen | |
| CANOPY GROWTH | 0,952 | -0,83 % | Canopy Growth Corp (2): Canopy Growth adds new Spectrum softgels in Australia | ||
| TILRAY BRANDS | 7,000 | 0,00 % | Tilray Brands: Handelsaussetzung - 02.12.2025 | ||
| INNOCAN PHARMA | 6,050 | -3,97 % | Innocan Pharma gibt Finanzergebnisse für 3. Quartal 2025 bekannt - mit Umsätzen von 21,6 Mio. USD | Herzliya, Israel und Calgary, Alberta - 27. November 2025 / IRW-Press / Innocan Pharma Corporation (CSE: INNO) (FWB: IP4) (OTC: INNPF) (das
"Unternehmen" oder "Innocan"), ein pharmazeutisches... ► Artikel lesen | |
| CRONOS GROUP | 2,208 | +4,05 % | Cronos Group Inc.: Cronos Group Reports 2025 Second Quarter Results | Net revenue in Q2 2025 increased by 21% year-over-year PEACE NATURALS® retained its position as the number one cannabis brand in Israel1 Highest-ever international and Israel revenue, fueled by strong... ► Artikel lesen | |
| SYNBIOTIC | 1,852 | -1,80 % | EQS-News: SYNBIOTIC SE: SYNBIOTIC verstärkt Präsenz auf internationalen Events und verfolgt Fortschritte in der Cannabisforschung | EQS-News: SYNBIOTIC SE
/ Schlagwort(e): Strategische Unternehmensentscheidung
SYNBIOTIC verstärkt Präsenz auf internationalen Events und verfolgt Fortschritte in der Cannabisforschung... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 5,600 | +1,73 % | Green Thumb Industries Reports Third Quarter 2025 Results | CHICAGO and VANCOUVER, British Columbia, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. ("Green Thumb" or the "Company") (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer... ► Artikel lesen | |
| CHRISTINA LAKE CANNABIS | 0,024 | +20,00 % | Christina Lake Cannabis Corp.: Christina Lake Cannabis Announces Debenture Extension | VANCOUVER, British Columbia, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Christina Lake Cannabis Corp. (the "Company" or "CLC" or "Christina Lake Cannabis") (CSE: CLC) (OTCQB: CLCFF) (FRANKFURT: CLB) announces... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 123,75 | +1,27 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy | Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA a2,3 receptor positive allosteric modulator Deepens Axsome's broad and innovative neuroscience portfolio with a synergistic... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 143,35 | -0,03 % | Jazz Pharmaceuticals präsentiert entscheidende Phase-3-Daten für Ziihera auf ASCO-GI-Symposium | ||
| JAGUAR HEALTH | 1,155 | 0,00 % | Jaguar Health, Inc.: Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study | Jaguar's requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved CanaleviaA novel non-antibiotic approach to diarrhea treatment is important because there... ► Artikel lesen | |
| TRULIEVE CANNABIS | 5,230 | +0,67 % | Trulieve Cannabis Corp.: Trulieve Reports Third Quarter 2025 Results Demonstrating Operational Discipline and Cash Flow Strength | Third quarter revenue of $288 million, with 59% gross margin
Year to date cash flow from operations of $214 million and free cash flow of $173 million*
Sold... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 9,400 | +6,21 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces Pricing of Public Offering | NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) ("Corbus" or the "Company"), an oncology and obesity company, today announced the pricing of... ► Artikel lesen | |
| AVALO THERAPEUTICS | 14,280 | +4,54 % | Avalo Therapeutics, Inc. - 8-K, Current Report |
FILAMENT HEALTH CORP gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FILAMENT HEALTH CORP finden Sie auf Wallstreet Online.